{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T07:15:41Z","timestamp":1789802141246,"version":"4.0.1"},"reference-count":104,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.beem.2020.101383","type":"journal-article","created":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T03:30:56Z","timestamp":1580441456000},"page":"101383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Thyroid-associated ophthalmopathy: Emergence of teprotumumab as a promising medical therapy"],"prefix":"10.1016","volume":"34","author":[{"given":"Terry J.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2020.101383_bib1","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves' ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2020.101383_bib2","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves' disease","volume":"375","author":"Smith","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2020.101383_bib3","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1167\/iovs.14-14002","article-title":"Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy","volume":"55","author":"Wang","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.beem.2020.101383_bib4","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1210\/en.2013-1576","article-title":"Cutting edge: retrobulbar inflammation, adipogenesis, and acute orbital congestion in a preclinical female mouse model of Graves' orbitopathy induced by thyrotropin receptor plasmid-in\u00a0vivo electroporation","volume":"154","author":"Moshkelgosha","year":"2013","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2020.101383_bib5","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1126\/science.2556796","article-title":"Molecular cloning of the thyrotropin receptor","volume":"246","author":"Parmentier","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.beem.2020.101383_bib6","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.autrev.2009.03.012","article-title":"TSH receptor autoantibodies","volume":"9","author":"Michalek","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.beem.2020.101383_bib7","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.3389\/fimmu.2019.01695","article-title":"Regulation of TSHR expression in the thyroid and thymus may contribute to TSHR tolerance failure in graves' disease patients via two distinct mechanisms","volume":"10","author":"Marin-Sanchez","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.beem.2020.101383_bib8","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1055\/a-0725-9297","article-title":"Reflections on thyroid autoimmunity: a personal overview from the past into the future","volume":"50","author":"Rapoport","year":"2018","journal-title":"Horm Metab Res = Hormon- und Stoffwechselforschung = Hormones et metab"},{"key":"10.1016\/j.beem.2020.101383_bib9","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1016\/j.ophtha.2011.03.030","article-title":"Clinical relevance of thyroid-stimulating immunoglobulins in graves' ophthalmopathy","volume":"118","author":"Ponto","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.beem.2020.101383_bib10","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.2147\/OPTH.S67098","article-title":"Thyroid-stimulating immunoglobulins as measured in a reporter bioassay are not detected in patients with Hashimoto's thyroiditis and ophthalmopathy or isolated upper eyelid retraction","volume":"8","author":"Wall","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.beem.2020.101383_bib11","first-page":"160008","article-title":"Thyroid antibody-negative euthyroid Graves' ophthalmopathy","author":"Tabasum","year":"2016","journal-title":"Endocrinol Diabetes Metabol Case Rep"},{"key":"10.1016\/j.beem.2020.101383_bib12","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1210\/jc.2009-1614","article-title":"Increased generation of fibrocytes in thyroid-associated ophthalmopathy","volume":"95","author":"Douglas","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2020.101383_bib13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/thy.2009.0278","article-title":"A\u00a0stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves' orbital preadipocyte fibroblasts","volume":"20","author":"Kumar","year":"2010","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2020.101383_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075100","article-title":"Thyrotropin regulates IL-6 expression in CD34+ fibrocytes: clear delineation of its cAMP-independent actions","volume":"8","author":"Raychaudhuri","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.beem.2020.101383_bib15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1210\/en.2018-00272","article-title":"HIF2A-LOX pathway promotes fibrotic tissue remodeling in thyroid-associated orbitopathy","volume":"160","author":"Hikage","year":"2019","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2020.101383_bib16","doi-asserted-by":"crossref","first-page":"E625","DOI":"10.1210\/jc.2013-3977","article-title":"Regulation of IL-1 receptor antagonist by TSH in fibrocytes and orbital fibroblasts","volume":"99","author":"Li","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2020.101383_bib17","doi-asserted-by":"crossref","first-page":"E1635","DOI":"10.1210\/jc.2014-1580","article-title":"Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes","volume":"99","author":"Chen","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2020.101383_bib18","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1089\/thy.2016.0243","article-title":"Thyrotropin and CD40L stimulate interleukin-12 expression in fibrocytes: implications for pathogenesis of thyroid-associated ophthalmopathy","volume":"26","author":"Wu","year":"2016","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2020.101383_bib19","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1006\/clin.1994.1144","article-title":"Evidence of fibroblast heterogeneity and the role of fibroblast subpopulations in fibrosis","volume":"72","author":"Fries","year":"1994","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.beem.2020.101383_bib20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1172\/JCI93555","article-title":"Fibroblast heterogeneity: implications for human disease","volume":"128","author":"Lynch","year":"2018","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.beem.2020.101383_bib21","first-page":"2620","article-title":"Evidence for cellular heterogeneity in primary cultures of human orbital fibroblasts","volume":"80","author":"Smith","year":"1995","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2020.101383_bib22","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/1521-4141(200202)32:2<477::AID-IMMU477>3.0.CO;2-U","article-title":"Fibroblast subsets in the human orbit: Thy-1+ and Thy-1- subpopulations exhibit distinct phenotypes","volume":"32","author":"Koumas","year":"2002","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.beem.2020.101383_bib23","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/105072502753600133","article-title":"Orbital fibroblasts exhibit a novel pattern of responses to proinflammatory cytokines: potential basis for the pathogenesis of thyroid-associated ophthalmopathy","volume":"12","author":"Smith","year":"2002","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2020.101383_bib24","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0002-9440(10)63488-8","article-title":"Thy-1 expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic phenotypes","volume":"163","author":"Koumas","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.beem.2020.101383_bib25","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1073\/pnas.91.11.5094","article-title":"Prostaglandin E2 elicits a morphological change in cultured orbital fibroblasts from patients with Graves ophthalmopathy","volume":"91","author":"Smith","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beem.2020.101383_bib26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF03403533","article-title":"Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair","volume":"1","author":"Bucala","year":"1994","journal-title":"Mol Med"},{"key":"10.1016\/j.beem.2020.101383_bib27","doi-asserted-by":"crossref","first-page":"8568","DOI":"10.1038\/s41598-019-45012-6","article-title":"Infiltrating CCR2(+) monocytes and their progenies, fibrocytes, contribute to colon fibrosis by inhibiting collagen degradation through the production of TIMP-1","volume":"9","author":"Kuroda","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.beem.2020.101383_bib28","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.matbio.2017.11.010","article-title":"Inflammation and fibrosis","volume":"68\u201369","author":"Mack","year":"2018","journal-title":"Matrix Biol"},{"key":"10.1016\/j.beem.2020.101383_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/cells8101210","article-title":"Depletion of bone marrow-derived fibrocytes attenuates TAA-induced liver fibrosis in mice","volume":"8","author":"Hempel","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.beem.2020.101383_bib30","doi-asserted-by":"crossref","first-page":"41357","DOI":"10.1074\/jbc.M104898200","article-title":"The autoimmune regulator (AIRE) is a DNA-binding protein","volume":"276","author":"Kumar","year":"2001","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.beem.2020.101383_bib31","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1126\/science.1075958","article-title":"Projection of an immunological self shadow within the thymus by the aire protein","volume":"298","author":"Anderson","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.beem.2020.101383_bib32","doi-asserted-by":"crossref","first-page":"7427","DOI":"10.1073\/pnas.1202064109","article-title":"Human fibrocytes coexpress thyroglobulin and thyrotropin receptor","volume":"109","author":"Fernando","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beem.2020.101383_bib33","doi-asserted-by":"crossref","first-page":"E1236","DOI":"10.1210\/jc.2013-4271","article-title":"Expression of thyrotropin receptor, thyroglobulin, sodium-iodide symporter, and thyroperoxidase by fibrocytes depends on AIRE","volume":"99","author":"Fernando","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2020.101383_bib34","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.94.12.6307","article-title":"The peripheral blood fibrocyte is a potent antigen-presenting cell capable of priming naive T cells in situ","volume":"94","author":"Chesney","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beem.2020.101383_bib35","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF03402138","article-title":"Interaction of Borrelia burgdorferi with peripheral blood fibrocytes, antigen-presenting cells with the potential for connective tissue targeting","volume":"5","author":"Grab","year":"1999","journal-title":"Mol Med"},{"key":"10.1016\/j.beem.2020.101383_bib36","doi-asserted-by":"crossref","first-page":"7556","DOI":"10.4049\/jimmunol.166.12.7556","article-title":"Peripheral blood fibrocytes: differentiation pathway and migration to wound sites","volume":"166","author":"Abe","year":"2001","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.beem.2020.101383_bib37","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1210\/jcem-73-2-307","article-title":"Increased induction of HLA-DR by interferon-gamma in cultured fibroblasts derived from patients with Graves' ophthalmopathy and pretibial dermopathy","volume":"73","author":"Heufelder","year":"1991","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2020.101383_bib38","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-2265.1992.tb02284.x","article-title":"Regulation by glucocorticoids of interferon gamma-induced HLA-DR antigen expression in cultured human orbital fibroblasts","volume":"37","author":"Heufelder","year":"1992","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2020.101383_bib39","doi-asserted-by":"crossref","first-page":"942","DOI":"10.4049\/jimmunol.168.2.942","article-title":"Igs from patients with Graves' disease induce the expression of T cell chemoattractants in their fibroblasts","volume":"168","author":"Pritchard","year":"2002","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.beem.2020.101383_bib40","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.4049\/jimmunol.170.12.6348","article-title":"Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway","volume":"170","author":"Pritchard","year":"2003","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.beem.2020.101383_bib41","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1210\/edrv-10-3-366","article-title":"Connective tissue, glycosaminoglycans, and diseases of the thyroid","volume":"10","author":"Smith","year":"1989","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2020.101383_bib42","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1210\/jcem-69-5-1019","article-title":"Hormonal regulation of hyaluronate synthesis in cultured human fibroblasts: evidence for differences between retroocular and dermal fibroblasts","volume":"69","author":"Smith","year":"1989","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2020.101383_bib43","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/0006-291X(75)90326-5","article-title":"Absence of hyaluronidase in cultured human skin fibroblasts","volume":"67","author":"Arbogast","year":"1975","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.beem.2020.101383_bib44","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1172\/JCI111642","article-title":"Dexamethasone regulation of glycosaminoglycan synthesis in cultured human skin fibroblasts. Similar effects of glucocorticoid and thyroid hormones","volume":"74","author":"Smith","year":"1984","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.beem.2020.101383_bib45","first-page":"4079","article-title":"Expression of hyaluronan synthase messenger ribonucleic acids and their induction by interleukin-1beta in human orbital fibroblasts: potential insight into the molecular pathogenesis of thyroid-associated ophthalmopathy","volume":"84","author":"Kaback","year":"1999","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2020.101383_bib46","doi-asserted-by":"crossref","first-page":"25117","DOI":"10.1074\/jbc.273.39.25117","article-title":"Molecular cloning and characterization of the human and mouse UDP-glucose dehydrogenase genes","volume":"273","author":"Spicer","year":"1998","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.beem.2020.101383_bib47","doi-asserted-by":"crossref","first-page":"24487","DOI":"10.1074\/jbc.M111.241166","article-title":"Divergent Sp1 protein levels may underlie differential expression of UDP-glucose dehydrogenase by fibroblasts: role in susceptibility to orbital Graves disease","volume":"286","author":"Tsui","year":"2011","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.beem.2020.101383_bib48","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1210\/jcem-31-3-315","article-title":"Radioisotopic thyroidolymphography in patients with Graves' disease","volume":"31","author":"Kriss","year":"1970","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2020.101383_bib49","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/105072502760043413","article-title":"Thyroglobulin in orbital tissues from patients with thyroid-associated ophthalmopathy: predominant localization in fibroadipose tissue","volume":"12","author":"Lisi","year":"2002","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2020.101383_bib50","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1089\/105072503322401041","article-title":"Glycosaminoglycans provide a binding site for thyroglobulin in orbital tissues of patients with thyroid-associated ophthalmopathy","volume":"13","author":"Marino","year":"2003","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2020.101383_bib51","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0140-6736(93)91475-2","article-title":"Expression of thyrotropin-receptor mRNA in healthy and Graves' disease retro-orbital tissue","volume":"342","author":"Feliciello","year":"1993","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.beem.2020.101383_bib52","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1089\/thy.1993.3.297","article-title":"Detection of TSH receptor RNA in cultured fibroblasts from patients with Graves' ophthalmopathy and pretibial dermopathy","volume":"3","author":"Heufelder","year":"1993","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2020.101383_bib53","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/BF03345273","article-title":"Novel aspects of orbital fibroblast pathology","volume":"27","author":"Smith","year":"2004","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.beem.2020.101383_bib54","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3341\/kjo.2015.29.4.213","article-title":"Clinical association of thyroid stimulating hormone receptor antibody levels with disease severity in the chronic inactive stage of graves' orbitopathy","volume":"29","author":"Woo","year":"2015","journal-title":"Kor J Ophthalmol"},{"key":"10.1016\/j.beem.2020.101383_bib55","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/08916939309014643","article-title":"Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy","volume":"16","author":"Weightman","year":"1993","journal-title":"Autoimmunity"},{"key":"10.1016\/j.beem.2020.101383_bib56","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","article-title":"Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease","volume":"181","author":"Tsui","year":"2008","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.beem.2020.101383_bib57","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1089\/thy.2018.0089","article-title":"Evidence that graves' ophthalmopathy immunoglobulins do not directly activate IGF-1 receptors","volume":"28","author":"Marcus-Samuels","year":"2018","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2020.101383_bib58","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1210\/en.2019-00055","article-title":"Arrestin-beta-1 Physically Scaffolds TSH and IGF1 receptors to enable crosstalk","volume":"160","author":"Krieger","year":"2019","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2020.101383_bib59","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1001\/archopht.120.3.380","article-title":"Insights into the pathogenesis of thyroid-associated orbitopathy: evolving rationale for therapy","volume":"120","author":"Kazim","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.beem.2020.101383_bib60","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1530\/EJE-18-0039","article-title":"Predictive score for the development or progression of Graves' orbitopathy in patients with newly diagnosed Graves' hyperthyroidism","volume":"178","author":"Wiersinga","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2020.101383_bib61","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S2213-8587(16)30046-8","article-title":"Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy","volume":"5","author":"Wiersinga","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2020.101383_bib62","article-title":"Orbital Radiotherapy plus concomitant steroids in moderate-to-severe graves' ophthalmopathy: good results after long-term follow-up","volume":"17","author":"Nicosia","year":"2019","journal-title":"Int J Endocrinol Metabol"},{"key":"10.1016\/j.beem.2020.101383_bib63","doi-asserted-by":"crossref","first-page":"D27","DOI":"10.1530\/EJE-19-0389","article-title":"Will biological agents supplant systemic glucocorticoids as the first-line treatment for thyroid-associated ophthalmopathy?","volume":"181","author":"Smith","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2020.101383_bib64","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1210\/jc.2005-0148","article-title":"Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy","volume":"90","author":"Kahaly","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2020.101383_bib65","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy","volume":"97","author":"Bartalena","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2020.101383_bib66","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1089\/thy.2006.0267","article-title":"Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy","volume":"17","author":"Le Moli","year":"2007","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2020.101383_bib67","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12020-016-0928-3","article-title":"Acute liver damage following intravenous glucocorticoid treatment for Graves' ophthalmopathy","volume":"54","author":"Moleti","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2020.101383_bib68","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000443828","article-title":"The 2016 European thyroid association\/European group on graves' orbitopathy guidelines for the management of graves' orbitopathy","volume":"5","author":"Bartalena","year":"2016","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.beem.2020.101383_bib69","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.beem.2020.101383_bib70","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/ncprheum0042","article-title":"B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus","volume":"2","author":"Eisenberg","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.beem.2020.101383_bib71","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0165-2478(03)00032-4","article-title":"B-cell depletion with rituximab-a targeted therapy for Graves' disease and autoimmune thyroiditis","volume":"88","author":"Hasselbalch","year":"2003","journal-title":"Immunol Lett"},{"key":"10.1016\/j.beem.2020.101383_bib72","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1530\/eje.1.02119","article-title":"Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression","volume":"154","author":"Salvi","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2020.101383_bib73","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1530\/eje.1.02140","article-title":"The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option","volume":"154","author":"El Fassi","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2020.101383_bib74","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1089\/thy.2006.16.709","article-title":"Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion","volume":"16","author":"El Fassi","year":"2006","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2020.101383_bib75","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study","volume":"100","author":"Salvi","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2020.101383_bib76","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with Graves' orbitopathy","volume":"100","author":"Stan","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2020.101383_bib77","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","article-title":"Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial","volume":"6","author":"Kahaly","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2020.101383_bib78","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2020.101383_bib79","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy: a randomized clinical trial","volume":"195","author":"Perez-Moreiras","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.beem.2020.101383_bib80","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/IOP.0000000000000037","article-title":"Treatment of active corticosteroid-resistant graves' orbitopathy","volume":"30","author":"Perez-Moreiras","year":"2014","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.beem.2020.101383_bib81","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nrd.2017.178","article-title":"Trends in GPCR drug discovery: new agents, targets and indications","volume":"16","author":"Hauser","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.beem.2020.101383_bib82","doi-asserted-by":"crossref","first-page":"9841","DOI":"10.1074\/jbc.C600014200","article-title":"A\u00a0low molecular weight agonist signals by binding to the transmembrane domain of thyroid-stimulating hormone receptor (TSHR) and luteinizing hormone\/chorionic gonadotropin receptor (LHCGR)","volume":"281","author":"Jaschke","year":"2006","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.beem.2020.101383_bib83","doi-asserted-by":"crossref","first-page":"12471","DOI":"10.1073\/pnas.0904506106","article-title":"Small-molecule agonists for the thyrotropin receptor stimulate thyroid function in human thyrocytes and mice","volume":"106","author":"Neumann","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beem.2020.101383_bib84","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1210\/jc.2010-1935","article-title":"A\u00a0new small-molecule antagonist inhibits Graves' disease antibody activation of the TSH receptor","volume":"96","author":"Neumann","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2020.101383_bib85","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1210\/en.2013-1835","article-title":"A\u00a0selective TSH receptor antagonist inhibits stimulation of thyroid function in female mice","volume":"155","author":"Neumann","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2020.101383_bib86","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1210\/en.2010-0199","article-title":"A\u00a0small molecule inverse agonist for the human thyroid-stimulating hormone receptor","volume":"151","author":"Neumann","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2020.101383_bib87","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1089\/1050725041692918","article-title":"Characteristics of a human monoclonal autoantibody to the thyrotropin receptor: sequence structure and function","volume":"14","author":"Sanders","year":"2004","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2020.101383_bib88","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1089\/thy.2005.15.672","article-title":"Characteristics of a monoclonal antibody to the thyrotropin receptor that acts as a powerful thyroid-stimulating autoantibody antagonist","volume":"15","author":"Sanders","year":"2005","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2020.101383_bib89","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1210\/en.2008-1800","article-title":"A\u00a0monoclonal antibody with thyrotropin (TSH) receptor inverse agonist and TSH antagonist activities binds to the receptor hinge region as well as to the leucine-rich domain","volume":"150","author":"Chen","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2020.101383_bib90","series-title":"Constitutive activity in receptors and other proteins","article-title":"TSH receptor monoclonal antibodies with agonist, antagonist, and agonist, and inverse agonist activities\/","author":"Sanders","year":"2010"},{"key":"10.1016\/j.beem.2020.101383_bib91","first-page":"81","article-title":"Crystal structure of the TSH receptor (TSHR) bound to a blocking-type TSHR autoantibody","volume":"46","author":"Sanders","year":"2011","journal-title":"J\u00a0Mol Endocrinol"},{"key":"10.1016\/j.beem.2020.101383_bib92","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1210\/en.2018-00306","article-title":"Immunotherapy with apitopes blocks the immune response to TSH receptor in HLA-DR transgenic mice","volume":"159","author":"Jansson","year":"2018","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2020.101383_bib93","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1089\/thy.2019.0036","article-title":"Antigen-specific immunotherapy with thyrotropin receptor peptides in graves' hyperthyroidism: a phase I study","volume":"29","author":"Pearce","year":"2019","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2020.101383_bib94","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.4049\/jimmunol.173.5.3564","article-title":"Synovial fibroblasts from patients with rheumatoid arthritis, like fibroblasts from Graves' disease, express high levels of IL-16 when treated with Igs against insulin-like growth factor-1 receptor","volume":"173","author":"Pritchard","year":"2004","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.beem.2020.101383_bib95","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1124\/pr.109.002469","article-title":"Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?","volume":"62","author":"Smith","year":"2010","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.beem.2020.101383_bib96","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007273","article-title":"High expression levels of total IGF-1R and sensitivity of NSCLC cells in\u00a0vitro to an anti-IGF-1R antibody (R1507)","volume":"4","author":"Gong","year":"2009","journal-title":"PloS One"},{"key":"10.1016\/j.beem.2020.101383_bib97","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2010.34.0000","article-title":"R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study","volume":"29","author":"Pappo","year":"2011","journal-title":"J\u00a0Clin Oncol : Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.beem.2020.101383_bib98","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/bcp.12228","article-title":"The adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapy","volume":"77","author":"Ma","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.beem.2020.101383_bib99","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2020.101383_bib100","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2265.2001.01241.x","article-title":"Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments","volume":"54","author":"Terwee","year":"2001","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2020.101383_bib101","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41433-018-0321-y","article-title":"Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis","volume":"33","author":"Douglas","year":"2019","journal-title":"Eye"},{"key":"10.1016\/j.beem.2020.101383_bib102","series-title":"American society of ophthalmic plastic & recontructive surgery (ASOPRS) annual fall meeting, Chicago, IL","article-title":"Teprotumumab in TED: diplopia outcome analysis (abstract)","author":"Douglas","year":"2018"},{"key":"10.1016\/j.beem.2020.101383_bib103","series-title":"American thyroid association (ATA) 88th annual meeting, Washington DC","article-title":"48-week follow-up of a multicenter, randomized, double-masked, placebo-controlled treatment trial of teprotumumab in thyroid-associated ophthalmopathy (abstract)","author":"Kahaly","year":"2018"},{"key":"10.1016\/j.beem.2020.101383_bib104","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N.\u00a0Engl. J. Med."}],"container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X20300105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X20300105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:56:11Z","timestamp":1761497771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X20300105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":104,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1521690X20300105"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2020.101383","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thyroid-associated ophthalmopathy: Emergence of teprotumumab as a promising medical therapy","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2020.101383","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101383"}}